Application of mobile health communication platform intervention in patients with obese coronary heart disease after PCI and sustainable health management

doi:10.3877/cma.j.issn.2095-9605.2020.01.006

Abstract

Abstract:

Objective

To explore the impact of the medical intervention model of building a mobile health communication platform on the clinical effect and health management of obese patients with coronary heart disease after PCI.

Methods

A total of 122 obese patients with coronary heart disease who underwent PCI treatment in our Department of Cardiology from March 2018 to October 2019 were randomly divided into a control group and a study group, with 61 patients in each group. Patients in the control group were followed up routinely after PCI treatment, while patients in the study group used mobile health communication platforms for intervention, and observed and recorded changes in blood lipid levels, intervention satisfaction, negative emotions, and medication compliance before and after intervention And the quality of life and adverse reactions of patients after surgery.

Results

After PCI treatment and intervention, negative emotions such as anxiety and depression, body mass index, and blood lipid levels in the study group patients were significantly improved (P<0.05). In addition, the study group's medication compliance, satisfaction with the intervention and incidence of postoperative adverse reactions were significantly better than the control group (P<0.05), and their quality of life was significantly higher than the control group (P<0.05).

Conclusions

Establishing a mobile health communication platform medical intervention model will help improve the weight management of obese coronary heart disease patients after PCI, improve clinical results and treatment satisfaction, but also improve patients 'negative emotions and enhance patients' medication compliance, controls blood lipid levels in patients to improve their prognosis and quality of life.

Key words: Coronary heart disease, Mobile, Communication platform, Health management, Obesity, Quality of life

Mingyu Yang, Nating Lai, Kangrong Li, Hangyu He. Application of mobile health communication platform intervention in patients with obese coronary heart disease after PCI and sustainable health management[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2020, 06(01): 27-32.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2020.01.006

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2020/V06/I01/27

Figures/Tables 7

References 29

[1]	Batty GD, Kivimaki M, Bell S. Comparison of risk factors for coronary heart disease morbidity versus mortality[Z]. Eur J Prev Cardiol, 2019, 16: 1-3.
[2]	高润霖. 冠心病疾病负担—中国出路[J]. 中国循环杂志, 2017, 32(01): 1-4.
[3]	胡盛寿，高润霖，刘力生, 等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34(03): 209-220.
[4]	李晓玲，陈燕燕. 肥胖伴糖尿病及冠心病患者的体重管理[J]. 中国循环杂志, 2019, 34(11): 1130-1133.
[5]	孙漾丽，孙兵兵，李征艳，等. 心脏康复干预对冠心病PCI术后患者左心室射血分数及运动耐力的影响[J]. 广东医学. 2018, 39(24): 3640-3643.
[6]	冠心病合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版), 2018, 10(06): 1-130.
[7]	韩雅玲. 冠心病介入治疗新进展[J]. 临床军医杂志, 2017, 45(06): 551-557.
[8]	武俊呈，杨娜，姚志鹏, 等. 经皮冠脉介入治疗术后死亡率与冠心病危险因素的研究进展[J]. 中国老年学杂志, 2018, 38(06): 1529-1532.
[9]	张传猛，杨瑞雪，万崇华, 等. 冠心病患者生命质量/患者报告结局的影响因素分析[J]. 广东医学, 2016, 37(04): 598-601.
[10]	刘奕婷，王巍，时景璞. PCI术后急性心肌梗死患者再发影响因素分析[J]. 中国公共卫生, 2016, 32(04): 558-562.
[11]	潘晓，黄惠桥，陶品月, 等. 移动医疗APP在PCI患者自我行为管理中的应用[J]. 广东医学, 2018, 39(16): 2498-2502.
[12]	中华医学会心血管病学分会介入心脏病学组，中华医学会心血管病学分会动脉粥样硬化与冠心病学组，中国医师协会心血管内科医师分会血栓防治专业委员会, 等. 稳定性冠心病诊断与治疗指南[J]. 中华心血管病杂志, 2018, 46(9): 680-694.
[13]	Wong MCS, Zhang DX, Wang HHX. Rapid emergence of atherosclerosis in Asia: a systematic review of coronary atherosclerotic heart disease epidemiology and implications for prevention and control strategies[J]. Current opinion in lipidology. 2015, 26(4): 257-269.
[14]	王卓清，李永豪，李玉茜, 等. 老年冠心病患者血流动力学变化及其临床意义[J]. 广东医学. 2017, 38(S2):74-75.
[15]	Zhang H, Chang R. Effects of Exercise after Percutaneous Coronary Intervention on Cardiac Function and Cardiovascular Adverse Events in Patients with Coronary Heart Disease: Systematic Review and Meta-Analysis[J]. J Sports Sci Med, 2019: 18(2): 213-222.
[16]	杨勇. 冠心病介入治疗的现状与研究进展综述[J]. 中西医结合心血管病电子杂志. 2016, 4(22): 11-12.
[17]	颜君，杨巧红，林春喜. 冠状动脉介入治疗术后患者服药依从性及其影响因素[J]. 实用医学杂志, 2015, 31(16): 2675-2678.
[18]	史利锋，林平. 经皮冠状动脉介入治疗患者术后心脏不良事件的发生情况及影响因素[J]. 中华护理杂志, 2015, 50(12): 1449-1453.
[19]	张改，陈巍，林平. 经皮冠状动脉介入治疗术后再狭窄的相关因素分析[J]. 中华护理杂志, 2015, 50(10): 1194-1198.
[20]	Moholdt T, Lavie CJ, Nauman J. Interaction of physical activity and body mass index on mortality in coronary heart disease: data from the Nord-Trϕndelag Health Study[J]. Am J Med, 2017, 130(8): 949.
[21]	Lavie CJ, De SA, Milani RV. Body composition and the obesity paradox in coronary heart disease: can heavier really be healthier?[J]. Heart, 2015, 101(20): 1610-1611.
[22]	潘晓，黄惠桥，陶品月, 等. 移动医疗APP在PCI患者自我行为管理中的应用[J]. 广东医学, 2018, 39(16): 2498-2502.
[23]	周慧迪，龚玲，杨芩. 健康管理模式对老年冠心病患者不良心脏事件和营养状态的影响[J]. 贵州医药, 2019, 43(05): 825-827.
[24]	王浩，姜秀芳，苏会芝, 等. 健康管理模式对老年冠心病患者不良生活习惯及相关并发症的影响[J]. 心血管康复医学杂志, 2019, 28(02): 142-147.
[25]	Bash LD, White K, Patel MD, et al. Cardiovascular Risk Factors and Secondary Events Among Acute and Chronic Stable Myocardial Infarction Patients: Findings from a Managed Care Database[J]. Cardiology and therapy, 2019, 8(2): 329-343.
[26]	杨剑，陈智明，温祝杜, 等. 健康管理对提高冠心病患者依从性降低危险因素的积极意义[J]. 中国医药科学, 2016, 6(13): 58-61.
[27]	王韵. 健康管理模式在老年冠心病病人中的应用[J]. 全科护理, 2015, 13(30): 3065-3067.
[28]	王浩，姜秀芳，苏会芝, 等. 健康管理模式对老年冠心病患者不良生活习惯及相关并发症的影响[J]. 心血管康复医学杂志, 2019, 28(02): 142-147.
[29]	赵月元，张爱华. 冠心病介入治疗患者自我管理行为与焦虑抑郁及生存质量的相关性[J]. 护理学杂志, 2016, 31(05): 8-11.

组别	例数	性别（男/女）	BMI(kg/m²)	平均年龄（岁）	平均病程（年）
对照组	61	37/34	30.21±1.73	53.82±11.38	3.34±1.01
研究组	61	36/35	30.35±1.51	54.15±10.57	3.29±0.92
t/χ²值	?	0.028	0.476	0.166	0.286
P值	?	0.867	0.635	0.868	0.775

组别	例数	性别（男/女）	BMI(kg/m²)	平均年龄（岁）	平均病程（年）
对照组	61	37/34	30.21±1.73	53.82±11.38	3.34±1.01
研究组	61	36/35	30.35±1.51	54.15±10.57	3.29±0.92
t/χ²值	?	0.028	0.476	0.166	0.286
P值	?	0.867	0.635	0.868	0.775

组别	例数（n）	焦虑评分（SAS）		抑郁评分（SDS）
组别	例数（n）	干预前	干预3个月后	干预前	干预3个月后
对照组	61	67.83±14.92	43.55±10.14#	64.87±10.96	45.61±9.94#
研究组	61	68.04±15.23	29.56±9.48^*#	65.11±13.19	28.17±10.05^*#
t值	?	0.077	7.871	0.109	9.636
P值	?	0.939	<0.001	0.913	<0.001

组别	例数（n）	焦虑评分（SAS）		抑郁评分（SDS）
组别	例数（n）	干预前	干预3个月后	干预前	干预3个月后
对照组	61	67.83±14.92	43.55±10.14#	64.87±10.96	45.61±9.94#
研究组	61	68.04±15.23	29.56±9.48^*#	65.11±13.19	28.17±10.05^*#
t值	?	0.077	7.871	0.109	9.636
P值	?	0.939	<0.001	0.913	<0.001

组别	服药依从性
组别	完全依从	基本依从	完全不依从	服药依从率
对照组	26（42.62%）	28（45.90%）	7（11.48%）	54（88.52%）
研究组	36（59.02%）	25（40.98%）	0（0）	61（100%）^*

Please choose a citation manager

Content to export